The sooner we up list the better for me personally
Post# of 30028
Posted On: 09/04/2014 11:04:58 AM
The sooner we up list the better for me personally. I plan on buying more AMBS shares on margin, which we'll be able to do once we get onto the NASDAQ.
Reverse Split? I am not afraid of it. Why? LymPro revenue, pure and simple.
I know I've mentioned this other company I was in before I rolled my profits over to AMBS, but the parallel is compelling. It's pps was doing nothing for a long time. Then they got this drug approved and started selling it. The first 2 or 3 quarter were a little slow and then sales went through the roof. The pps went from $8 to $81 in about 8 months.
Once LymPro revenue starts in January the stock price will keep going up as sales revenues go up. They will be directly proportional. I'd love to be at only .15 cents on November 1st and do a RS and up list. I'd buy more shares on margin right away! Would I be worried that the pps would back slide? No, not at .15 cents!! If we had spiked to .60 cents and then did a RS and up listed, then I'd be more cautious about buying more shares on margin right away, thinking that the pps had spiked too rapidly. But not if we are only trading at .15 cents!! There is a silver lining to be undervalued, especially if you have confidence revenues are coming just 1 month later.
Without a JV Partner for LymPro this year, the pps might not get as high as we were thinking prior to the up list. But for the reasons I described above, that's O.K. Once revenue starts up we won't have to share it with a JV partner. Someone mentioned, maybe Jason, that with these Research Companies doing AD clinical trials, we really don't need a sales partner that much. We can hook these companies up ourselves. Its once we get FDA approval that a sales partner might be nice....marketing it to the general public.
So don't get too out of sorts about being undervalued right now. I'm encouraged by management's commitment to up list no matter what. They know LymPro revenue is coming, I know LymPro revenue is coming, you know LymPro revenue is coming, and the market is going to take notice of our pps next year after we make a mad dash from .15 cents to many, many multiples higher.
Reverse Split? I am not afraid of it. Why? LymPro revenue, pure and simple.
I know I've mentioned this other company I was in before I rolled my profits over to AMBS, but the parallel is compelling. It's pps was doing nothing for a long time. Then they got this drug approved and started selling it. The first 2 or 3 quarter were a little slow and then sales went through the roof. The pps went from $8 to $81 in about 8 months.
Once LymPro revenue starts in January the stock price will keep going up as sales revenues go up. They will be directly proportional. I'd love to be at only .15 cents on November 1st and do a RS and up list. I'd buy more shares on margin right away! Would I be worried that the pps would back slide? No, not at .15 cents!! If we had spiked to .60 cents and then did a RS and up listed, then I'd be more cautious about buying more shares on margin right away, thinking that the pps had spiked too rapidly. But not if we are only trading at .15 cents!! There is a silver lining to be undervalued, especially if you have confidence revenues are coming just 1 month later.
Without a JV Partner for LymPro this year, the pps might not get as high as we were thinking prior to the up list. But for the reasons I described above, that's O.K. Once revenue starts up we won't have to share it with a JV partner. Someone mentioned, maybe Jason, that with these Research Companies doing AD clinical trials, we really don't need a sales partner that much. We can hook these companies up ourselves. Its once we get FDA approval that a sales partner might be nice....marketing it to the general public.
So don't get too out of sorts about being undervalued right now. I'm encouraged by management's commitment to up list no matter what. They know LymPro revenue is coming, I know LymPro revenue is coming, you know LymPro revenue is coming, and the market is going to take notice of our pps next year after we make a mad dash from .15 cents to many, many multiples higher.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼